-Firstpost.com After the UPA-II released its self-congratulatory 79-page ‘Report card to the People', National Advisory Council (NAC) member and leading social activist Aruna Roy has come down heavily on the government for its poor performance in the social sector. Roy, an instrumental force behind the Right to Information Act, criticised the government for stalling on essential legislations such as the Food Security Bill, the Land Acquisition Bill and the Lokpal Bill. Roy spoke...

-The Times of India NEW DELHI: If Delhi government has to make sure that residents don't eat pesticide-laced food, it will have to push neighboring states to reduce their pesticide usage. Most of Delhi's fruits and vegetables come from Haryana, Uttar Pradesh and Himachal Pradesh. Agricultural experts say that while High Court-appointed panel's recommendations on monitoring pesticide residue levels are welcome, much more needs to be done. According to the latest report...

Argumentative Indians are at it again! After sparring over the poverty line and the actual number of poor, India's renowned economists have fired up a fresh debate over the extent of malnutrition. In the earlier debate, the Planning Commission ‘reduced' poverty on paper disregarding NSSO and official committees, including the NCEUS, which determined that 77% Indians survived on less than Rs 20 a day. Columbia university economist Arvind Panagariya has...

-The Hindu Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...